{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:39:50Z","timestamp":1785555590184,"version":"3.56.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","seminarsinnephrology.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.semnephrol.2016.10.005","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T03:46:24Z","timestamp":1485834384000},"page":"30-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Low GDP Solution and Glucose-Sparing Strategies for Peritoneal Dialysis"],"prefix":"10.1016","volume":"37","author":[{"given":"Cheuk Chun","family":"Szeto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2016.10.005_bib1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.jrn.2013.01.019","article-title":"Systemic and local impact of glucose and glucose degradation products in peritoneal dialysis solution","volume":"23","author":"Kim","year":"2013","journal-title":"J Ren Nutr"},{"issue":"Suppl 2","key":"10.1016\/j.semnephrol.2016.10.005_bib2","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1177\/089686080002002S08","article-title":"Strategies to reduce glucose exposure in peritoneal dialysis patients","volume":"20","author":"Holmes","year":"2000","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1523-1755.2001.059002463.x","article-title":"High glucose-induced PKC activation mediates TGF-beta 1 and fibronectin synthesis by peritoneal mesothelial cells","volume":"59","author":"Ha","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib4","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1523-1755.2004.00491.x","article-title":"Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by human peritoneal mesothelial cells","volume":"65","author":"Lee","year":"2004","journal-title":"Kidney Int"},{"issue":"Suppl 2","key":"10.1016\/j.semnephrol.2016.10.005_bib5","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1177\/089686080002002S04","article-title":"Effect of high glucose on peritoneal mesothelial cell biology","volume":"20","author":"Ha","year":"2000","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0014-5793(99)01642-7","article-title":"Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis","volume":"463","author":"Inagi","year":"1999","journal-title":"FEBS Lett"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib7","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1093\/ndt\/gfn273","article-title":"3,4-Dideoxyglucosone-3-ene as a mediator of peritoneal demesothelization","volume":"23","author":"Santamar\u00eda","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib8","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1038\/sj.ki.5001924","article-title":"Glucose sparing in peritoneal dialysis: implications and metrics","volume":"103","author":"Holmes","year":"2006","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.amjcard.2007.03.107","article-title":"Postprandial hyperglycemia\/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor","volume":"100","author":"O\u05f3Keefe","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-139-2-200307150-00010","article-title":"Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study","volume":"139","author":"Li","year":"2003","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.semnephrol.2016.10.005_bib11","first-page":"S5","article-title":"History, chemical and pharmaceutical development of icodextrin","volume":"14","author":"Alsop","year":"1993","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib12","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1046\/j.1523-1755.62.s81.5.x","article-title":"Pharmacokinetics of icodextrin in peritoneal dialysis patients","volume":"81","author":"Moberly","year":"2002","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1159\/000363417","article-title":"Practical considerations when prescribing icodextrin: a narrative review","volume":"39","author":"Silver","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib14","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1093\/ndt\/gft050","article-title":"Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials","volume":"28","author":"Cho","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3747\/pdi.2009.00264","article-title":"Comparison of icodextrin and glucose solutions for long dwell exchange in peritoneal dialysis: a meta-analysis of randomized controlled trials","volume":"31","author":"Qi","year":"2011","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib16","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2012100987","article-title":"Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients","volume":"24","author":"Li","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/089686080102100308","article-title":"Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism","volume":"21","author":"Bredie","year":"2001","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib18","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1038\/sj.ki.5002613","article-title":"Echocardiographic, electrocardiographic and blood pressure changes induced by icodextrin solution in diabetic patients on peritoneal dialysis","volume":"108","author":"Paniagua","year":"2008","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib19","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1046\/j.1523-1755.2003.00887.x","article-title":"Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study","volume":"63","author":"Konings","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib20","first-page":"9","article-title":"Icodextrin eliminates phosphate and ameliorates cardiac hypertrophy and valvular calcification in patients with end-stage renal disease and diabetes mellitus undergoing peritoneal dialysis","volume":"29","author":"Hiramatsu","year":"2013","journal-title":"Adv Perit Dial"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/089686080502500509","article-title":"Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?","volume":"25","author":"Martikainen","year":"2005","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib22","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.10041110","article-title":"Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial","volume":"6","author":"Takatori","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib23","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/ndt\/gfr580","article-title":"Effects of icodextrin on patient survival and technique success in patients undergoing peritoneal dialysis","volume":"27","author":"Han","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/ki.1994.300","article-title":"A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter investigation of icodextrin in ambulatory peritoneal dialysis","volume":"46","author":"Mistry","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/089686080902900409","article-title":"Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients","volume":"29","author":"Paniagua","year":"2009","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib26","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/ndt\/15.6.862","article-title":"Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis","volume":"15","author":"Woodrow","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2369-2-2","article-title":"Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload","volume":"2","author":"Johnson","year":"2001","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib28","first-page":"80","article-title":"Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients","volume":"17","author":"Amici","year":"2001","journal-title":"Adv Perit Dial"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib29","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/ndt\/gfi197","article-title":"Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients","volume":"21","author":"Furuya","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/089686080202200615","article-title":"Beneficial effect of icodextrin on the hypertriglyceridemia of CAPD patients","volume":"22","author":"Sisca","year":"2002","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000086553","article-title":"Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients","volume":"23","author":"Martikainen","year":"2005","journal-title":"Blood Purif"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/08860220802595500","article-title":"Icodextrin dialysate improves nutritional and inflammatory profiles in peritoneal dialysis patients","volume":"31","author":"Lin","year":"2009","journal-title":"Ren Fail"},{"issue":"Suppl 3","key":"10.1016\/j.semnephrol.2016.10.005_bib33","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1177\/089686080802803s19","article-title":"Icodextrin and intraperitoneal inflammation","volume":"28","author":"Moriishi","year":"2008","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib34","doi-asserted-by":"crossref","first-page":"424915","DOI":"10.1155\/2013\/424915","article-title":"Bimodal solutions or twice-daily icodextrin to enhance ultrafiltration in peritoneal dialysis patients","volume":"2013","author":"Dousdampanis","year":"2013","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000126924","article-title":"The utility of two daytime icodextrin exchanges to reduce dextrose exposure in automated peritoneal dialysis patients: a pilot study of nine patients","volume":"26","author":"Gobin","year":"2008","journal-title":"Blood Purif"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3747\/pdi.2009.00175","article-title":"Double-dose icodextrin to increase ultrafiltration in PD patients with inadequate ultrafiltration","volume":"31","author":"Ballout","year":"2011","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11255-010-9716-9","article-title":"Two icodextrin exchanges per day in peritoneal dialysis patients with ultrafiltration failure: one center\u05f3s experience and review of the literature","volume":"43","author":"Dousdampanis","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/089686080902900411","article-title":"Effects of twice-daily icodextrin administration on blood pressure and left ventricular mass in patients on continuous ambulatory peritoneal dialysis","volume":"29","author":"Sav","year":"2009","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1440-1797.2009.01186.x","article-title":"Two daytime icodextrin exchanges decrease brain natriuretic peptide levels and improve cardiac functions in continuous ambulatory peritoneal dialysis patients","volume":"15","author":"Sav","year":"2010","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib40","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/089686080402400613","article-title":"Enhanced ultrafiltration using 7.5% icodextrin\/1.36% glucose combination dialysate: a pilot study","volume":"24","author":"Dallas","year":"2004","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib41","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/089686080902900410","article-title":"A combined crystalloid and colloid Pd solution as a glucose-sparing strategy for volume control in high-transport apd patients: a prospective multicenter study","volume":"29","author":"Freida","year":"2009","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/089686080902900404","article-title":"Amino acid-based peritoneal dialysis solutions for malnutrition: new perspectives","volume":"29","author":"Tjiong","year":"2009","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0272-6386(98)70131-3","article-title":"Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study","volume":"32","author":"Jones","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0272-6386(03)00421-9","article-title":"A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD","volume":"42","author":"Li","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib45","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/089686080602600414","article-title":"How to avoid glucose degradation products in peritoneal dialysis fluids","volume":"26","author":"Erixon","year":"2006","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib46","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/ndt\/gfh013","article-title":"Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells","volume":"19","author":"Witowski","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib47","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/039139880302600205","article-title":"Peritoneal leukocyte survival and respiratory burst responses in patients treated with a low glucose degradation and high pH peritoneal dialysis fluid","volume":"26","author":"Jonasson","year":"2003","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib48","first-page":"343","article-title":"Heat sterilized PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes","volume":"39","author":"Wieslander","year":"1993","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib49","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/j.1523-1755.2004.00879.x","article-title":"Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane","volume":"66","author":"Mortier","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib50","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1523-1755.2003.00705.x","article-title":"Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?","volume":"63","author":"Zeier","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib51","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.2337\/diabetes.54.8.2424","article-title":"3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells","volume":"54","author":"Justo","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib52","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1097\/01.ASN.0000060681.91079.30","article-title":"Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane","volume":"14","author":"Mortier","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/089686080402400105","article-title":"Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products","volume":"24","author":"Wieczorowska-Tobis","year":"2004","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib54","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1097\/01.ASN.0000086475.83211.DF","article-title":"Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis","volume":"14","author":"Haas","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib55","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/089686080802800214","article-title":"The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial","volume":"28","author":"Choi","year":"2008","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib56","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/ndt\/gfp054","article-title":"Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study","volume":"24","author":"Kim","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl:","key":"10.1016\/j.semnephrol.2016.10.005_bib57","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1046\/j.1440-1797.8.s.6.x","article-title":"Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report","volume":"8","author":"Kim","year":"2003","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib58","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/ndt\/gfr451","article-title":"Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study","volume":"27","author":"Park","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib59","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3747\/pdi.2010.00176","article-title":"A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products","volume":"32","author":"Lai","year":"2012","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib60","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/ndt\/gfn673","article-title":"Short-term effects of bicarbonate\/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study","volume":"24","author":"Pajek","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib61","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/089686080902900610","article-title":"Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution","volume":"29","author":"Weiss","year":"2009","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib62","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1046\/j.1523-1755.1998.00167.x","article-title":"Randomized long-term evaluation of bicarbonate-buffered CAPD solution","volume":"54","author":"Feriani","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib63","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/089686080002000506","article-title":"A long-term study of a bicarbonate\/lactate-based peritoneal dialysis solution--clinical benefits. The Bicarbonate\/Lactate Study Group","volume":"20","author":"Tranaeus","year":"2000","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib64","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/ndt\/gfq357","article-title":"Low-GDP peritoneal dialysis fluid (\u05f3balance\u05f3) has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothelial cells than a standard fluid","volume":"26","author":"Bajo","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib65","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3747\/pdi.2011.00279","article-title":"The effect of low-GDP solution on ultrafiltration and solute transport in continuous ambulatory peritoneal dialysis patients","volume":"33","author":"Cho","year":"2013","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib66","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.ki.5002574","article-title":"Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function","volume":"73","author":"Fan","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib67","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/ndt\/gfl559","article-title":"Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial","volume":"22","author":"Szeto","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib68","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1681\/ASN.2011121201","article-title":"Biocompatible versus standard peritoneal dialysis fluid - the balANZ trial","volume":"23","author":"Johnson","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib69","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/ndt\/gfq087","article-title":"Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study","volume":"25","author":"Haag-Weber","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib70","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3747\/pdi.2010.00315","article-title":"Influence of bicarbonate\/low-GDP peritoneal dialysis fluid (BicaVera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells","volume":"32","author":"Fernandez-Perpen","year":"2012","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib71","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/ndt\/13.12.3165","article-title":"A controlled trial of two bicarbonate-containing dialysis fluids for CAPD--final report","volume":"13","author":"Coles","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib72","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1523-1755.2001.00497.x","article-title":"Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products","volume":"59","author":"Rippe","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib73","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1523-1755.2004.00747.x","article-title":"The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane","volume":"66","author":"Williams","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib74","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/ki.2013.190","article-title":"The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients","volume":"84","author":"Cho","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007554.pub2","article-title":"Biocompatible dialysis fluids for peritoneal dialysis","volume":"3","author":"Cho","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib76","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3747\/pdi.2012.00331","article-title":"Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials","volume":"34","author":"Seo","year":"2014","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib77","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000368235","article-title":"Effect of neutral pH and low-glucose degradation product-containing peritoneal dialysis solution on residual renal function in peritoneal dialysis patients: a meta-analysis","volume":"129","author":"Wang","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib78","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.05410514","article-title":"Effect of neutral-pH, low-glucose degradation product peritoneal dialysis solutions on residual renal function, urine volume, and ultrafiltration: a systematic review and meta-analysis","volume":"10","author":"Yohanna","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib79","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib80","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3747\/pdi.2014.00278","article-title":"ISPD cardiovascular and metabolic guidelines in adult peritoneal dialysis patients part II - management of various cardiovascular complications","volume":"35","author":"Wang","year":"2015","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib81","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3747\/pdi.2014.00279","article-title":"ISPD cardiovascular and metabolic guidelines in adult peritoneal dialysis patients part I - assessment and management of various cardiovascular risk factors","volume":"35","author":"Wang","year":"2015","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib82","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1093\/ndt\/gfh326","article-title":"Biocompatibility pattern of a bicarbonate\/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study","volume":"19","author":"Fusshoeller","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib83","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1523-1755.1998.00849.x","article-title":"Bicarbonate and bicarbonate\/lactate peritoneal dialysis solutions for the treatment of infusion pain","volume":"53","author":"Mactier","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib84","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3747\/pdi.2012.00052","article-title":"The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial","volume":"32","author":"Johnson","year":"2012","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib85","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1093\/ndt\/gfs314","article-title":"The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial","volume":"27","author":"Johnson","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib86","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2014.12.017","article-title":"Economic evaluation of neutral-pH, low-glucose degradation product peritoneal dialysis solutions compared with standard solutions: a secondary analysis of the balANZ trial","volume":"65","author":"Howard","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib87","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1046\/j.1523-1755.2003.00209.x","article-title":"Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS)","volume":"64","author":"Marshall","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib88","first-page":"170","article-title":"Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study","volume":"20","author":"le Poole","year":"2004","journal-title":"Adv Perit Dial"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3747\/pdi.2010.00101","article-title":"\"NEPP\" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO","volume":"32","author":"le Poole","year":"2012","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib90","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3747\/pdi.2010.00115","article-title":"A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation","volume":"32","author":"le Poole","year":"2012","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib91","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1053\/j.ajkd.2012.05.018","article-title":"A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial","volume":"60","author":"Lui","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib92","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3747\/pdi.2014.00125","article-title":"Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers","volume":"35","author":"Yung","year":"2015","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib93","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000371554","article-title":"The benefit of a glucose-sparing PD therapy on glycemic control measured by serum fructosamine in diabetic patients in a randomized, controlled trial (IMPENDIA)","volume":"129","author":"Li","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.semnephrol.2016.10.005_bib94","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jacl.2014.03.007","article-title":"Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA\/EDEN trials","volume":"8","author":"Sniderman","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"Suppl 1","key":"10.1016\/j.semnephrol.2016.10.005_bib95","article-title":"Icodextrin 7.5% dialysate for overnight exchange in patients treated with CCPD","volume":"19","author":"Bajo","year":"1999","journal-title":"Perit Dial Int"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929516301000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929516301000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T01:59:03Z","timestamp":1658541543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929516301000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0270929516301000"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2016.10.005","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low GDP Solution and Glucose-Sparing Strategies for Peritoneal Dialysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2016.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}